Osthole Inhibits M1 Macrophage Polarization and Attenuates Osteolysis in a Mouse Skull Model

Excessive bone resorption due to increased inflammatory factors is a common feature of inflammatory lytic bone diseases. This group of diseases is effectively treated with drugs. In recent years, many studies have reported that traditional Chinese medicine herbs have substantial effects on inflammation, osteoclast differentiation and maturation, and bone destruction. Herein, we investigated the effects of osthole (OST) on lipopolysaccharide- (LPS-) induced macrophage polarization, inflammatory responses, and osteolysis. In vitro, we used immunofluorescence and quantitative real-time polymerase chain reaction assays to confirm whether bone marrow-derived macrophages showed an increased expression of inflammatory factors, such as interleukin-6, iNOS, CCR7, and CD86, in the presence of LPS. However, we found that such expression was suppressed and that the M2 macrophage expression increased in the presence of OST. OST reduced LPS- and RANKL-induced intracellular reactive oxygen species production in the bone marrow-derived macrophages. Further, it potently suppressed osteoclast differentiation and osteoclast-specific gene expression by suppressing the P38/MAPK and NF-κB pathways. Consistent with the in vitro observations, OST greatly ameliorated LPS-induced bone resorption and modulated the ratio of macrophages at the site of osteolysis. Taken together, OST has great potential for use in the management of osteolytic diseases.


Introduction
"Bone remodeling" occurs throughout a person's life [1], in which osteoblasts (OBs) and osteoclasts (OCs) play an essential role. OBs play a central role in bone formation by forming new bone matrix proteins and differentiating into osteocytes, whereas OCs are the only cells with bone resorption function in the body. However, inflammatory OCs are often abnormally active and cause osteolysis due to inflammation and hormonal changes, including rheumatoid arthritis (RA) [2], chronic periodontal disease [3], osteomyelitis [4], and peri-implantitis [5]. The search for drugs with fewer toxic side effects is an effective means to improve the treatment outcomes of these diseases.
Bacteria generated at the interface of implants and the bones can interfere with the aggregation of bone marrowderived macrophages (BMMs). Thus, they further promote the differentiation of BMMs into OCs and release large amounts of proinflammatory factors, such as interleukin-(IL-) 1, tumor necrosis factor-α, and IL-6 [6,7]. Macrophages exhibit different phenotypes, mainly the proinflammatory type and anti-inflammatory M2 type, depending on the changes in the bone immune microenvironment. An increase in M1 macrophage production is observed in many inflammatory bone diseases, for example, in periodontitis, there is an M1 polarization of the macrophage phenotype, a phenotype that leads to the loss of periodontal attachment and resorption of alveolar bone [8]. In RA, proinflammatory factors secreted by M1 macrophages exacerbate the symptoms, whereas anti-inflammatory factors secreted by M2 macrophages alleviate such. In addition, the anti-inflammatory cytokines IL-10 and transforming growth factor-β, which are secreted by M2 macrophages, can be used to treat RA [9,10]. When M1 macrophages dominate implants, there are usually inflammation around the implants and imbalance in bone metabolism, which eventually lead to implant failure [11]. These findings demonstrate the detrimental effects of the proinflammatory M1 phenotype in inflammatory bone diseases; therefore, investigators have focused on macrophage polarization in the hope of finding effective targets for the treatment of inflammatory bone diseases.
BMMs differentiate into OCs without the induction of M-CSF and RANKL ( [12,13]. M-CSF mainly maintains the survival, proliferation, and maturation of monocytemacrophages, induces BMMs to express RANK receptors, and becomes OC precursor cells. Body cells are released by OBs and fibroblasts, and during inflammatory responses, RANKL from activated T and B lymphocytes binds to RANK on OC precursor cells, activating Toll-like receptors, mainly tumor necrosis factor receptor-associated fraction 6, further activating the AKT, NF-κB, and MAPK pathways and promoting OC formation. According to the literature ( [14][15][16], osthole (OST) has anti-inflammatory, thrombotic, antitumor, and antiallergic effects. OST ameliorated kidney damage by inhibiting KHK activity, preventing oxidative stress via nuclear factor erythroid 2-related factor (Nrf2) activation, and reducing renal lipotoxicity [17]. OST increased the protein expression of p38 mitogen-activated protein kinase (MAPK) and type I collagen and enhances the differentiation and maturation of osteoblasts in vitro [18]. However, the effect of OST on macrophage polarization and osteoclast differentiation has not been extensively studied. Therefore, we investigated the effects of OST on lipopolysaccharide-(LPS-) induced M1 macrophage polarization, as well as the resulting osteoprotective effects.

Cell
Culture. The BMMs were prepared as described previously [19]. Briefly, the BMMs were extracted from the femurs and tibias of 6-week-old C57/BL6 male mice. Isolated cells were cultured in complete α-MEM (α-MEM supplemented with 10% fetal bovine serum, 100 U/mL penicillin/streptomycin, and 30 ng/mL M-CSF). The BMMs were obtained by culturing the cells in a humid environment containing 5% CO 2 at 37°C for 5 days.
2.3. Cell Viability Assay. To assess whether OST was toxic to the BMMs, the BMMs were seeded at a density of 1 × 10 4 cells/well and supplied with complete α-MEM, M-CSF (30 ng/mL) and increasing concentrations of OST (0, 1.5, 3, 6. 25, 12.5, 25, 50, 100, 200, and 400 μM). Following treatment with OST, the cells were incubated for 24, 48, and 72 h in a 96-well plate. After treatment, 10 μL of CCK-8 solution was added to each well and incubated for 2 h, and the absorbance at 450 nm was measured using an enzyme marker. The effect of OST on cell viability was expressed as percentage cell viability, with the viability of the control cells set to 100%, and the half-inhibitory concentration was calculated for 48 and 72 h.

Immunofluorescence
Staining. The BMMs (2 × 10 5 cells/ well) were plated in confocal culture plates (Seahorse Bioscience, North Billerica, USA) and allowed to attach overnight. The cells were treated with 100 ng/mL LPS to induce M1 polarization. During polarization induction, different concentrations of OST (6.25, 12.5, and 25 μM) were added for 24 h. The BMMs were fixed in paraformaldehyde with 0.1% Triton X-100 (Sigma, USA). Goat serum (4%) was used to block nonspecific binding. The cells were then incubated overnight with iNOS and CD206 primary antibodies (CST, USA; dilution 1 : 200). The fluorescent secondary antibodies were incubated at room temperature for 1 h. The cells were stained with 4,6-diamidino-2-phenylindole for 5 min and observed under a fluorescence microscope.
2.5. Reactive Oxygen Species (ROS) Assay. Intracellular ROS formation was detected using a DCFH-DA probe. The BMMs were inoculated in 96-well plates (black wall/clear bottom) at a density of 2 × 10 5 cells/well and then stimulated with M-CSF treatment alone or M-CSF, LPS, and different concentrations of OST (6.25, 12.5, and 25 μM) for 24 h. DCFH-DA and Hoechst (dilution, 1 : 1000) were loaded in serum-free α-MEM for 20 min at 37°C. Fluorescence intensity was measured using a fluorescence microscope (DMI8; Leica) and a multifunctional microplate reader (Infinite F500; Monidorf Dicken, Switzerland).

Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR). The BMMs were inoculated in 6-well plates at a density of 4 × 10 5 cells/well, and after the cells were plastered, the experimental and control groups were treated with the same immunofluorescence, with 3 subwells for each group. Total RNA was extracted from the macrophages using the TRIzol method, and the purity and concentration of the extracted RNA were tested using a NanoDrop 2000/ 2000c spectrophotometer. The extracted RNA was reversetranscribed into cDNA using a PrimeScript Reverse Transcription Kit. The PCR reaction parameters were as follows: 95°C for 5 s, 60°C for 30 s, 40 cycles, using GAPDH as the 2.9. qRT-PCR Analysis of OC-Related Gene Expression. After the BMMs were counted, they were inoculated in 6-well plates at a ratio of approximately 4 × 10 5 cells/well. M-CSF (30 ng/mL) was routinely added to the medium, and the medium containing 50 ng/mL RANKL and different concentrations of OST (6.25, 12.5, and 25 μM) was replaced after 24 h. The medium was changed every other day, and the cells were treated with drugs for 5 days, followed by RNA extraction, reverse transcription, and PCR amplification, as described in Section 2.6. The mouse primer sequences used are listed in Table 2.

Western Blot Analysis.
To determine the effect of OST on RANKL-induced signaling, we measured the total cellular proteins at different time points. The proteins were extracted from the BMMs treated with 25 μM OST for 8 h, followed by stimulation with RANKL (50 ng/mL) for 10, 20, 30, and 60 min (short time course). The untreated cells were considered as mock controls (0 time point). The cultured cells were lysed with RIPA lysis buffer containing phosphatase and protease inhibitors for 10 min to obtain the total value. The protein concentration was determined using bicinchoninic acid assay. Thirty micrograms of the total cellular proteins was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes. After blocking in 5% (w/v) skim milk for 1 h, the primary antibodies (GAPDH, 1 : 1000; P-P65, 1 : 1000; P65, 1 : 1000; P-ERK, 1 : 1000; ERK, 1 : 1000; P-P38, 1 : 1000; P38, 1 : 1000; P-JNK, 1 : 1000; and JNK, 1 : 1000) were incubated at 4°C overnight. Thereafter, the secondary antibodies were incubated for 1 h at room temperature, and the fluorescence signals were determined using an Odyssey imaging system (Li-Cor, Lincoln, NE).

LPS-Induced Calvarial Osteolysis Mice
Model. All animal experiments were approved by the Ethics Committee of Shanghai Jiao Tong University School of Medicine. Twenty C57BL/6 female mice (age: 6 weeks, weight: 20 ± 0:10 g) were randomly divided into four groups (five mice per group): the sham-operated (injected with PBS), the LPS group (injected with 10 mg/kg LPS and PBS), the LPS +low-dose OST group (injected with LPS and 1.5 mg/kg OST), and the LPS+high-dose OST group (injected with  3 Oxidative Medicine and Cellular Longevity LPS and 7.5 mg/kg OST). After anesthetizing the mice, we implanted a gelatin sponge (4 × 4 × 2 mm) soaked with PBS or LPS (200 μg) in the calvaria. In the groups, PBS and OST were intraperitoneally injected every other day over a 14-day period. No adverse effects or deaths occurred in any mouse group during the experimental period. At the end of the experiment, the mice were sacrificed, and the dissected cranial bones were fixed in 4% paraformaldehyde for 48 h for subsequent analysis.

Histological Staining and Histomorphometric Analysis.
The calvarial samples were decalcified in 10% EDTA (pH: 7.4) for 2 weeks, and 4 μM tissue sections were cut into sections. The sections were stained with hematoxylin and eosin and TRAP. Digital images were acquired using an Axio Scope A1 light microscope (ZEISS, Germany). The number of OCs was quantified using the ImageJ software.
2.14. Tissue Immunofluorescence Staining. Antigen repair was first performed by placing the sections in 0.1 mol/L sodium citrate repair solution, heating them in a microwave oven for antigen repair, and cooling them for 30 min. The sections were soaked in 10% goat serum for 1 h to remove nonspecific staining; the goat serum was discarded; and the sections were incubated with rabbit anti-mouse iNOS and CD206 at a 1 : 500 dilution and incubated overnight at 4°C. After incubation with the primary antibody, the cells were incubated with the fluorescent secondary antibody (1 : 1000) for 1 h, protected from light, sealed, and dried at room temperature, and images were collected under a fluorescence microscope.
2.15. Statistical Analysis. GraphPad Prism 8.0 was used to process and analyze the data obtained from the experiments. The t-test was used between two samples, and one-way ANOVA was used between multiple samples, with p < 0:05, p < 0:01, and p < 0:001 indicating significant differences.

OST Exerted No Cytotoxic Effects at Low Concentrations.
The CCK-8 analysis showed that low concentrations of OST were not cytotoxic to the BMMs; 25 μM and lower concentrations did not exert cytotoxic effects at 24, 48, and 72 h. The half-inhibitory concentration of OST was 269.7 μM at 24 h, 141.2 μM at 48 h, and 100.5 μM at 72 h (Figure 1(b)). We selected three groups that were not toxic to the cells (6.25, 12.5, and 25 μM) for the subsequent experiments.
3.2. OST Inhibited ROS Production in the LPS-and RANKL-Induced BMMs. After induction with 100 ng/mL LPS and 50 ng/mL RANKL, the ROS expression in the BMMs increased (Figures 2(a) and 2(b)). OST inhibited ROS production in the BMMs at different degrees, and the higher the OST concentration, the weaker the DCFH-DA fluorescence . The DCF fluorescence intensity in each well was evaluated and quantified. OST treatment markedly reduced intracellular ROS production compared with LPS or RANKL treatment alone. The fluorescence intensity was also significantly lower in the presence of OST than in 520ðp < 0:05Þ. In summary, our findings demonstrate that OST acts as an inhibitor to reduce ROS signaling pathways during ROS production in the LPS-and RANKL-induced BMMs (Figure 3).

OST Inhibited LPS-Induced Polarization of the M1
Macrophages. In this experiment, the effect of different concentrations of OST on the expression of the LPS-induced M1 macrophage surface marker iNOS and M2 macrophage surface marker CD206 was examined using immunofluorescence. As shown in Figure 4(a), the expression of iNOS was elevated after LPS treatment in the addition group compared with that in the control group; the degree of decrease differed between the addition and LPS only groups (M1 group), and the most obvious decrease was observed in the M1+25 μmol/ L OST group (Figure 4(b)). In contrast, CD206 showed an opposite trend, with no significant change in its expression in the M1 group compared with that in the control group; however, the degree of elevation differed between the dosing and M1 groups, and the M1+25 μmol/L OST group showed the strongest CD206 fluorescence intensity (Figure 4(c)).

Oxidative Medicine and Cellular Longevity
We then employed qRT-PCR to evaluate the effect of OST on the LPS-induced inflammation-related genes in the BMMs. LPS induced the polarization of the BMMs to the M1 type, and the expression of the proinflammatory genes (iNOS, IL-6, CCR7, and CD86) significantly increased ðp < 0:001Þ. Meanwhile, the expression of iNOS, CD86, IL-6, and CCR7 significantly decreased after the addition of the different concentrations of OST compared with those after LPS treatment ðp < 0:01Þ. The iNOS, IL-6, and CCR7 levels decreased in a concentration-dependent manner with OST. In contrast, the transcript levels of IL-10, an inflammatory factor, increased at different degrees in the dosing group, and the most significant increase was observed in the 25 μM OST group. These results showed that OST inhibited the expression of the M1 proinflammatory factors, and the inhibitory effect was positively correlated with the concentration and increased the expression of the M2 proinflammatory factors to some extent.

OST Reduced RANKL-Induced OC Differentiation.
To further investigate whether OST could inhibit OC differentiation, we used 50 ng/mL RANKL to induce OC precursor cells to differentiate into OCs. The TRAP staining kit could stain OC-associated enzymes purple red under acidic conditions, and under TRAP staining, the cells larger than three nuclei and stained purple red were OCs. As shown in Figure 5 The expression of the OC-specific genes was analyzed using qRT-PCR. We investigated the results of the RANKL and OST interventions for 5 days. The expression of the OC-specific genes, including NFATc1, CTR, CTSK, V-ATPase d2, TRAP, c-Fos, and DC-STAMP, increased in the control group after RANKL stimulation; conversely, the expression was significantly suppressed partly in a dosedependent manner after OST treatment at the three concentrations of 6.25, 12.5, and 25 μM (Figure 5(d)). NFATc1 played an important role in OC differentiation; c-Fos assisted in NFATc1 activation; and CTSK, c-Fos, TRAP, and DC-STAMP decreased the transcript levels in a dosedependent manner. These results collectively showed that OST inhibited OC differentiation by downregulating the OC marker genes during OC differentiation, with 25 μM OST yielding the most effective inhibition.

OST Inhibited the Phosphorylation of the NF-κB and MAPK Pathway-Related Proteins.
To further investigate the mechanism related to OST inhibition of osteolysis, we detected the protein expression in the NF-κB and MAPK pathways using western blotting and analyzed the protein    Oxidative Medicine and Cellular Longevity expression in the RANKL and RANKL+25 μM OST groups via short-term stimulation with RANKL. As shown in Figure 6(a), the expression of P-P38, P-P65, and P-ERK increased and gradually decreased over time upon stimulation with RANKL for 10 min, indicating that the addition of RANKL stimulated the activation of the NF-κB and MAPK pathways in a short period. The RANKL+25 μM OST group showed a different protein expression at 10 min. The P-P38 and P-P65 expression decreased in the RANKL+25 μM OST group compared with that in the unspiked group, whereas the P-ERK and P-JNK expression did not differ between them. The expression of the related proteins in the two groups was analyzed and counted, as shown in Figures 6(b) and 6(c). The expression of P-P38 in the RANKL+25 μM OST group decreased at 10, 20, and 30 min compared with that in the RANKL-plus alone group ðp < 0:05Þ; the expression of P-P65 also decreased at 10 and 30 min in the RANKL+25 μM OST group compared with that in the RANKL-plus alone group ðp < 0:05Þ. Taken together, OST exerted its antibreakage effect by inhibiting the NF-κB and P38/MAPK pathways activated by RANKL (Figure 3).

OST Suppressed LPS-Induced Calvarial Osteolysis In
Vivo. We further investigated the potential application of OST in the treatment of inflammatory bone loss. We used LPS-induced inflammatory osteolysis in a mouse model of cranial bone injury. Gelatin sponge blocks impregnated with PBS or LPS (10 mg/kg) were implanted into the skulls of the mice to induce bone loss. The mice in each treatment group were injected subcutaneously with PBS or OST (low dose of 1.5 mg/kg or high dose of 7.5 mg/kg) into the sagittal suture of the skullcap on alternate days for 14 days. The 3D-CT reconstruction is shown in Figure 7(a). The skull surface of the LPS group showed extensive bone erosion, with deep and large resorption pits. In contrast, bone loss was significantly reduced in the mice treated with OST. Morphometric analysis showed a significant improvement in the bone volume compared with that after LPS treatment. There was a modest increase in the BV/TV (Figure 7(b)) compared with that in the sham-operated group. Similarly, bone porosity was reduced in the OST-treated animals compared with that in the LPS-treated animals (Figure 7(c)). Histological and histomorphometric analyses of the cranial sections were performed to further confirm the   Oxidative Medicine and Cellular Longevity osteoprotective effects of OST. The hematoxylin and eosinand TRAP-stained sections showed extensive osteolytic destruction of cranial bone tissue in the LPS group, which contained a large number of TRAP-positive OCs on the surface of the osteolytically destroyed cranial bone (Figure 7(d)). Osteolytic bone loss and the number of OCs significantly decreased by approximately 26% and 55% in the low-and high-dose OST treatment groups, respectively (Figure 7(e)).

OST Decreased the Expression of iNOS and Increased the Expression of CD206 at the Site of LPS-Induced Skull Lysis.
To further investigate whether OST treatment also has a role in regulating macrophages in vivo, we investigated the expression of the related proteins in the tissues using immunofluorescence and observed the expression of M1 macrophage marker protein iNOS and M2 macrophage marker protein CD206 in the tissues surrounding the skull lysis of the mice. As shown in Figure 8(a), a large amount of red fluorescence was visible at the edge of the tissue and inside the tissue, and the expression of iNOS increased ðp < 0:05Þ in the LPS group. The expression of iNOS decreased in both the high-and low-dose treatment groups and the red fluorescence was almost invisible in the high-dose group ðp < 0:05Þ. The green fluorescence indicated the expression of CD206 and compared with the LPS group, the high-and low-dose treatment groups showed an increased area of green staining and increased CD206 expression ðp < 0:05Þ. Therefore, OST decreased the expression of iNOS and increased the expression of CD206 at the site of LPSinduced cranial lysis in the mice.

Discussion
Chronic inflammatory bone diseases, such as chronic periodontitis and RA, are autoimmune diseases that seriously affect human health. Currently, the main method of treating inflammatory bone diseases is pharmacological treatment, which includes NSAIDs, bisphosphonates, denosumab, tissue proteinase K inhibitors, and anabolic agents [20,21]). However, the side effects and high price of these drugs limit their clinical application. Therefore, the development of new drugs for inflammatory bone diseases is imperative [22]. Currently, traditional Chinese medicine is gradually gaining attention for regulating the balance of bone metabolism because of its advantages of multiple pathways, multiple targets, and few toxic side effects.
Macrophage polarization during osteolysis is common. One study reported that in synovial joints under physiological conditions, macrophages remain quiescent along with fibroblasts, and when arthritis occurs, macrophages polarize to the proinflammatory M1 type according to changes in the microenvironment [23]. During the progressive phase of RA, most infiltrating macrophages are under the M1 type; the production of inflammatory cytokines, such as IL-6 and IL-23, can polarize primitive T cells into pathogenic Th17 cells, which promotes the production of OCs and thus initiates the process of osteolysis [24]. When macrophages

11
Oxidative Medicine and Cellular Longevity polarize to the anti-inflammatory M2 type, they secrete IL-10 and Arg-1 anti-inflammatory factors, and IL-10, an important immunomodulatory factor, can inhibit osteoclastogenesis and play an osteoprotective role in periodontal disease [24,25]. Natural compounds, such as kinsenoside, quercetin, and fargesin, have been found to modulate macrophage polarization and suppress OC activity, highlighting their potential as alternative therapeutics for disorders of bone metabolism [26][27][28].
LPS activates macrophages and polarizes them toward the M1 type, which is the classical induction method for M1 macrophages [29]. OST has an inhibitory effect on inflammation; however, it is not clear whether it affects the polarization of macrophages. In this experiment, the effect of OST on macrophage behavior was investigated by inducing BMMs toward M1 using 100 ng/mL of LPS. Using immunofluorescence and qRT-PCR, we found that LPS induced polarization of the BMMs toward the M1 type and increased the production of the proinflammatory factors. The decrease in the production of the inflammatory factors was most dominant after the addition of 25 μM OST, indicating that OST could reduce the proportion of M1 macrophages and increase the proportion of M2 macrophages to some extent. Moreover, qRT-PCR showed that the expression of the proinflammatory factor IL-10 also increased to some extent after the addition of OST; however, it has also been reported in the literature that OST can attenuate the infiltration of M2 macrophages around pancreatic cancer tumors to inhibit the progression [30], which may be attributed to the fact that the inflammatory microenvironment is fundamentally different from the tumor microenvironment, and a different microenvironment leads to very different changes in macrophages.
There is a strong link between inflammation and osteolysis, with most inflammatory factors primarily activating the RANK/RANKL/OPG signaling pathway, which consequently triggers the promotion of OC differentiation, leading to an imbalance in bone remodeling and bone loss.
In our study, OST was found to have an inhibitory effect on OC formation and function in vitro. At concentrations of 6.25-25 μM, there was no cytotoxic effect observed; osteoclastogenesis was significantly inhibited; and the expression of the OC-specific genes, including NFATC1, c-Fos, TRAP, CTR, CTSK, and V-ATPase d2, was suppressed. Further, OC differentiation was inhibited. Western blotting revealed that OST inhibited RANKL-induced P38/MAPK and NF-κB signaling. The RANKL-induced signaling pathways, including the NF-κB and p38 pathways, are generally critical for OC differentiation and survival [31]. There is accumulating evidence that the P38/MAPK pathway plays a key role in activating OC differentiation [32]. In our study, OST was inhibited by reducing the phosphorylation of P38 and P65, which contributed to the inhibition of RANKL-induced OC differentiation. Furthermore, NFATc1 is a master transcription factor that is closely regulated by NF-κB activity [33]. Therefore, we demonstrated that OST decreased RANKL-induced P38/MAPK and NF-κB activities, thereby inhibiting OC differentiation.
Increasing evidence indicates that ROS production underpins various pathological conditions, such as inflam-mation and osteoporosis [34,35]. An increase in ROS production can accelerate bone resorption by OCs, accelerate OB bone apoptosis, and cause an imbalance in bone metabolism. ROS enhances the activation of the NF-κB and MAPK pathways and induces the expression of inflammatory genes and OC-related genes [36]. This experiment demonstrated that OST could reduce cell damage caused by oxidative stress, which is one of the mechanisms of its antiinflammatory effect, and indirectly showed the inhibitory effect of OST on OCs.
To ascertain the beneficial effects of OST in the treatment of these conditions, we used LPS, a potent stimulator, to induce inflammatory bone loss via the recruitment and activation of OC bone resorption [37].
Consistent with our in vitro findings, OST significantly reduced OCs in the bone tissue, indicating that OC recruitment and formation were inhibited. OST reduced the proportion of M1 macrophages and increased that of M2 macrophages at the site of inflammatory osteolysis. Despite the promising effects of OST on OC activity, there are some limitations to this study. Bone remodeling is maintained in vivo through OB formation and OC resorption. The effects of OST on OB and OC biology and function must be investigated to determine any deleterious effects on these cells. In addition, OST weakened the inflammatory effect of the M1 macrophages and promoted the anti-inflammatory effect to some extent in our study. Further studies are needed to determine whether it affects M2 polarization.
In summary, OST can exert anti-inflammatory and antiosteolytic effects in vitro and in vivo by regulating the ratio of macrophages to inflammation and is a potential drug for the treatment of inflammatory osteolysis.

Data Availability
The datasets generated or analyzed during this study are available in the [Baidu Netdisk] repository, link: https:// pan.baidu.com/s/1pNDEcZk1LKLOfi_PBoX8Ig?pwd=z5l0.